Stephens Reiterates Overweight Rating for Ardent Health Partners (NYSE:ARDT)

Ardent Health Partners (NYSE:ARDT - Get Free Report)'s stock had its "overweight" rating restated by equities research analysts at Stephens in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $21.00 target price on the stock. Stephens' price objective would suggest a potential upside of 39.17% from the company's previous close.

A number of other analysts have also issued reports on ARDT. Royal Bank of Canada restated an "outperform" rating and set a $21.00 target price on shares of Ardent Health Partners in a research report on Thursday, May 15th. Mizuho reduced their price target on Ardent Health Partners from $19.00 to $18.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 9th. Morgan Stanley reduced their target price on Ardent Health Partners from $23.50 to $22.00 and set an "overweight" rating for the company in a research note on Tuesday, January 21st. Finally, Guggenheim increased their target price on Ardent Health Partners from $16.00 to $18.00 and gave the stock a "buy" rating in a report on Friday, May 9th. Two equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $20.67.

Ardent Health Partners Stock Performance

NYSE ARDT opened at $15.09 on Tuesday. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.91 and a quick ratio of 1.78. The stock has a market capitalization of $2.16 billion and a PE ratio of 9.26. Ardent Health Partners has a 1-year low of $11.31 and a 1-year high of $20.72. The business has a 50 day simple moving average of $13.16 and a two-hundred day simple moving average of $14.79.

Ardent Health Partners (NYSE:ARDT - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.21 by $0.08. The company had revenue of $1.50 billion for the quarter, compared to analyst estimates of $1.50 billion. On average, research analysts predict that Ardent Health Partners will post 1.23 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. bought a new position in shares of Ardent Health Partners in the third quarter valued at approximately $154,000. US Bancorp DE acquired a new stake in Ardent Health Partners during the 4th quarter valued at $31,000. Ventas Inc. purchased a new stake in Ardent Health Partners in the 4th quarter worth about $159,570,000. Barclays PLC lifted its position in shares of Ardent Health Partners by 24.7% in the fourth quarter. Barclays PLC now owns 26,177 shares of the company's stock worth $447,000 after purchasing an additional 5,185 shares in the last quarter. Finally, Oliver Luxxe Assets LLC purchased a new position in Ardent Health Partners during the fourth quarter valued at approximately $1,465,000.

About Ardent Health Partners

Ardent Health Partners, Inc owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.